Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, et al.
Science (2023) Vol. 381, Iss. 6659, pp. 794-799
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo Augusto Massarico Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 46
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Qinheng Zheng, Ziyang Zhang, Keelan Z. Guiley, et al.
Nature Chemical Biology (2024) Vol. 20, Iss. 9, pp. 1114-1122
Open Access | Times Cited: 32
Molecular glues for protein-protein interactions: Progressing toward a new dream
Markella Konstantinidou, Michelle R. Arkin
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1064-1088
Open Access | Times Cited: 25
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Induced protein degradation for therapeutics: past, present, and future
Hojong Yoon, Justine C. Rutter, Yen-Der Li, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 1
Open Access | Times Cited: 21
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Stuart L. Schreiber
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1050-1063
Open Access | Times Cited: 21
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 727-736
Open Access | Times Cited: 16
Decoding the functional impact of the cancer genome through protein–protein interactions
Haian Fu, Xiulei Mo, Andrei A. Ivanov
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Edward W. Tate, Lior Soday, Ana Losada de la Lastra, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 4, pp. 240-260
Closed Access | Times Cited: 14
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
Xiaoshen Ma, David L. Sloman, Ruchia Duggal, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11024-11052
Closed Access | Times Cited: 11
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
Alok K. Sharma, Jun Pei, Yue Yang, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 2, pp. 105650-105650
Open Access | Times Cited: 10
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Tonia Kirschner, Matthias Müller, Daniel Rauh
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6044-6051
Closed Access | Times Cited: 9
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket
Johannes Morstein, Vickie Bowcut, Micah C. Fernando, et al.
Cell (2024)
Open Access | Times Cited: 9
Emerging strategies for prospective discovery of molecular glue degraders
Baiyun Wang, Shiyun Cao, Ning Zheng
Current Opinion in Structural Biology (2024) Vol. 86, pp. 102811-102811
Closed Access | Times Cited: 8
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Hidenori Kitai, Philip H. Choi, Yu Chi Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Junya Sango, Saul Carcamo, Maria Sirenko, et al.
Nature (2024) Vol. 636, Iss. 8041, pp. 241-250
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top